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ABSTRACT
Muscle-invasive bladder cancer accounts for 25% of bladder cancer cases and represents a spectrum of disease, 
which can result in significant morbidity and mortality for anyone affected. Current management has evolved 
through years of research and clinical practice. It is based on a risk-benefit approach, which is often tailored to 
the individual requirements of patients and involves cystectomy, neoadjuvant and adjuvant therapies, and mul-
timodal surveillance paradigms to achieve high survival rates. Multiple guidelines exist to assist the clinicians 
in this decision-making process, but their adherence is often variable. In this article, we aimed to review the 4 
most commonly used guidelines from the European Association of Urology, the National Institute for Health 
and Care Excellence, the National Comprehensive Cancer Network, and the American Urological Association.
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Introduction
Bladder cancer is the 6th most common cancer 
in men and the 17th most common cancer in 
women.[1] Each year, 275,000 people are diag-
nosed with this disease, and 108,000 die from 
it. In industrialized countries, 90% of bladder 
cancers are urothelial or transitional cell carci-
nomas, whereas squamous cell carcinomas are 
more prevalent in developing nations. The most 
common preventable risk factor associated with 
bladder cancer is smoking, and nonpreventable 
risk factors include increasing age and family 
history. Nonmetastatic bladder cancer is sepa-
rated into non–muscle-invasive (75% of cases) 
and muscle-invasive disease (25% of cases).
In 2018, the worldwide age-standardized inci-
dence rate (per 100,000) was 9.6 for men and 
2.4 for women, with a cumulative risk of 1.08 
for men and 0.27 for women. Overall, the high-
est age-standardized incidence for men was re-
ported in Greece (40.4) and in Lebanon (9.4) 
for women. The age-standardized worldwide 
mortality was 3.2 in men and 2.3 in women.[2]
In this review, we aimed to summarize the 
commonly used guidelines developed for 
muscle-invasive bladder cancer (MIBC) from 
4 prominent organizations. It is worthwhile 
to note that although these clinical guidelines 
present the best available evidence, they will 
not always lead to the best outcome. Clinical 
expertise and patient values and preferences 
will always have to be taken into consideration.
Methods
A guideline-focused PubMed search on the 
topic of MIBC was performed from 2015 to 
present, and the websites of urological and on-
cological societies were manually searched to 
identify the most relevant guidelines. A thor-
ough review of the guidelines that are most 
commonly used in practice was also under-
taken, namely the American Urological Asso-
ciation (AUA), the National Comprehensive 
Cancer Network (NCCN), the National Insti-
tute for Health and Care Excellence (NICE) 
and the European Association of Urology 
(EAU) guidelines. Each guideline was recently 
updated and was based on extensive literature 
review by an expert panel.
The AUA Guideline
The AUA guideline was last updated in 2017, and 
no amendment has been published since then.
[1] The panel consisted of 14 members, and the 
draft guideline document was distributed to 128 
Ahead of Print
peer reviewers, 67 of whom submitted comments. Where sufficient 
evidence existed, a strength rating of “A” (high), “B” (moderate), 
or “C” (low) was assigned for support of “strong,” “moderate,” or 
“conditional” recommendations. In the absence of sufficient evi-
dence, “clinical principles” and “expert opinions” were issued. 
The NICE Guideline
The NICE guideline was created by a panel of 15 members, 
which included medical professionals, technical experts, and lay 
public representatives.[2] Non-muscle- and muscle-invasive dis-
eases were included in the same document. The guidelines were 
published in February 2015 and reviewed in 2019. No subse-
quent evidence was deemed strong enough to amend any of the 
existing recommendations. The recommendations varied from 
“must” (signifying a legal duty), “should” (strong recommen-
dation), and “to consider” (suggesting a case-by-case analysis). 
The EUA Guideline
The EUA guideline was formed by a panel of 14 medical profes-
sionals.[3] The first MIBC-specific guideline was issued in 2004 
and has been regularly updated since then. The latest update was 
in 2020. The recommendations were based on a strength rating, 
the basis of which was the modified Grading of Recommenda-
tions, Assessment, Development, and Evaluation methodology. 
This addressed a number of key factors, namely, the quality of 
evidence, the extent of the effect, and the balance between de-
sirable and undesirable outcomes, among others. The strength 
of each recommendation was subsequently represented by the 
words “strong” or “weak.”
The NCCN Guideline
The NCCN guideline was formed by a panel of 35 medical 
professionals, technical experts, and lay representatives com-
missioned by this USA-based Network.[4] It was first published 
in 1998 and has been regularly updated subsequently, most re-
cently, in May 2020. The guideline refers to both non-muscle- 
and muscle-invasive diseases and uses treatment algorithms and 
flowcharts to display the recommended management strategies. 
Evidence is categorized as “1” (high-level evidence with uni-
form consensus), “2A” (lower-level evidence with uniform con-
sensus), “2B” (lower-level evidence with consensus), and “3” 
(any level of evidence with major disagreement). Categories of 
preference are also mentioned, ranging from “preferred inter-
vention” to “other recommended intervention” and “useful in 
certain circumstances.”
Guideline Recommendations: Assessment and Diagnosis 
Lifestyle modification
All the guidelines acknowledge the correlation between tobacco 
smoking and bladder cancer and suggest that smoking cessa-
tion should be encouraged in all patients.[3] The AUA and EAU 
guidelines also recognize the increased risk of bladder cancer 
conferred by previous radiotherapy treatments, with the EAU 
advising closer monitoring for younger patients.[4,5] The EAU 
also recommends informing workers regarding the occupational 
hazards with potentially carcinogenic substances, such as aro-
matic amines. They also caution the clinicians to avoid piogli-
tazone administration in patients with previous or active bladder 
cancer because of increased risk of recurrence or progression.[5]
Pathology
Muscle-invasive cancers are often high-grade urothelial cancers; 
therefore, prognostic information is primarily obtained through 
identification of the morphological subtype instead of its grade.
[6,7] All the guidelines agree that the World Health Organization 
(WHO) grading system is to be followed but disagree on the 
version to be used. The NCCN follows the 2016 guideline, the 
AUA and EAU follow the 2004 guideline, and the NICE follows 
the 1973 classification. An important distinction between these 
WHO classifications is that the 1973 classification introduced 
significant ambiguity over the G2 tumor group and the grad-
ing of G1/2 and G2/3 groups, whereas the 2004 classification 
introduced the concept of low- and high-grade tumors in addi-
tion to a new category, the papillary urothelial neoplasm of low 
malignant potential.[5,6] In terms of molecular markers, they do 
not form part of standard clinical practice despite some evidence 
of improved histological grading accuracy, but they may be in-
cluded in future classifications.[2,7]
There is a general consensus that pathology reports should in-
clude certain pathologic features, such as the presence of muscu-
laris propria (detrusor muscle) and whether it has been invaded, 
the depth of invasion, and the presence of carcinoma in-situ 
(CIS) or variant histology.
Diagnostic Evaluation
The most common presenting complaint observed in patients 
with bladder cancer is hematuria. Other symptoms include fre-
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• A number of guidelines have been published on muscle-inva-
sive bladder cancer, each suggesting a variable management 
plan.
• Cystoscopy is always clinically indicated in the diagnostic 
phase.
• Appropriate staging of the cancer is required to ensure appro-
priate treatment.
• Radical cystectomy often forms a part of the management plan 
in localized disease.
• In case of guideline discrepancy, a holistic approach catering 
to the individual patient characteristics is required to ensure a 
personalized management strategy.
Main Points:
quency, urgency, dysuria, and, in cases of advanced tumors, 
pelvic pain and features of urinary tract obstruction. Once re-
ferred, the general consensus is that rectal and vaginal bimanual 
examination should be performed after an examination under 
anesthesia before or after a transurethral resection of the bladder 
tumor (TURBT) to assess whether there is a palpable tumor or it 
is fixed to the pelvic wall.[8] The results of the clinical examina-
tion should always be interpreted with care. 
Cystoscopy
All the guidelines agree that a cystoscopic evaluation of the 
entire urethra and bladder should be performed before any re-
section. Evaluation should include documentation of the tumor 
site, size, appearance (papillary or solid), and a description of 
any mucosal abnormalities[9]. However, if the tumor has already 
been visualized via an imaging study, the EAU guideline allows 
for omission of the cystoscopy, with the patient proceeding di-
rectly to TURBT for histological diagnosis.[5]
Currently, white light cystoscopy (WLC) is the gold standard 
recommended by the 4 major guidelines for the assessment and 
staging of bladder cancer. Use of photodynamic diagnosis or 
narrow-band imaging, in conjunction with WLC, is recommend-
ed by the NICE because of the increased sensitivity it confers for 
non–muscle-invasive bladder cancer (NMIBC), particularly CIS 
because it is more sensitive for papillary lesions and CIS.[10,11] 
These novel techniques need to be performed by experienced 
surgeons to reduce the false-positive results.[11]
Imaging
There is a growing evidence that a combined imaging and endo-
scopic approach confers improved diagnostic accuracy for upper 
urinary tract tumors.[12,13] EAU guidelines support this approach 
by advising that if a tumor has been unequivocally visualized 
with imaging studies, such as computed tomography (CT), mag-
netic resonance imaging (MRI), or ultrasound (US), the patient 
can proceed directly to a preoperative cystoscopy and TURBT.[3]
Cytology
Evaluation of cytology samples can be confounded by urinary 
tract infections, stones, and low cellular yields. However, at the 
hands of experienced clinicians, specificity can exceed 90%.[14] 
A negative cytology can, therefore, never exclude a tumor, but it 
has high sensitivity for high-grade tumors and CIS. Examination 
includes analysis of the voided urine or of bladder washings for 
exfoliated cancer cells. Currently, there are no known markers 
specific for the diagnosis of invasive bladder cancer.[15]
A standardized reporting system known as the “Paris System,” 
published in 2016, is used to characterize the diagnostic cate-
gories of urinary cytology.[16] Per the NICE guidelines, use of 
any urinary biomarkers is not a substitute for cystoscopy in the 
preliminary stages of bladder cancer investigation or during the 
follow-up period after treatment unless this is in the context of a 
clinical research study.[2]
Staging
The treatment strategies and prognosis of bladder cancer are 
dependent on the tumor stage and grade.[21] In clinical practice, 
the tumor, node, metastasis classification (2017, 8th edition) is 
recommended. There is also evidence that vascular and lym-
phatic invasion confers independent prognostic significance.
[17,18] NMIBC (formerly superficial bladder cancer) encompasses 
Ta, T1, and CIS tumors, whereas T2–4 tumors are classified as 
MIBCs (Table 1). Histologically, a low or high grade is also at-
tributed to urothelial carcinomas. 
CT and MRI of the abdomen and pelvis are the most commonly 
used techniques in bladder cancer staging. They are used before 
TURBT to establish the extent of tumor invasion locally to the 
lymph nodes, upper urinary tract, or distant organs.[19-22] There is 
evidence that MRI is better than CT for staging; however, nei-
ther can accurately diagnose the microscopic invasion of peri-
vesical fat; therefore, their principal aim should be to detect T3b 
disease or higher.[22-24]
Where CT or MRI is used, all the guidelines agree that they 
should be accompanied by intravenous contrast with delayed 
imaging to allow for evaluation of the renal pelvis and ureters for 
upper urinary tract carcinomas. Evidence suggests that CT urog-
raphy offers the highest diagnostic accuracy with good overall 
sensitivity (0.67–1.0) and specificity (0.93–0.99) for the upper 
urinary tract carcinomas.[19,25,26] Additionally, if hydronephrosis 
is present on imaging, it is associated with advanced disease and 
poor oncological outcome.[25] If CT urography is contraindicated 
because of renal dysfunction or iodine-based contrast allergy, 
MRI urography can be offered as an alternative. The caveat is 
that the glomerular filtration rate must be greater than 30 mL-1 
and that there is no acute renal failure to avoid nephrogenic sys-
temic fibrosis.[27] If both CT and MRI are contraindicated, renal 
US or noncontrast CT can be used in conjunction with retro-
grade ureteropyelography per the NCCN guidelines.[4]
Furthermore, chest imaging should always be performed owing to 
the strong association between bladder cancer and smoking. As a 
minimum, a chest X-ray should be performed in nonsmokers, but 
ideally, a CT should be conducted in all patients owing to the in-
creased sensitivity in evaluating metastatic cancer.[28] This would 
follow the recommendations of the AUA, EAU, and NCCN.
Per the NCCN guidelines, a complete chemistry profile and 
complete blood count should be performed during the staging 
process. If alkaline phosphatase is negative and there are no 
symptoms or signs suggestive of bone or brain metastases, no 
Omorphos et al. Guideline of guidelines: Muscle-invasive bladder cancer
further investigations are required because of the low likelihood 
of such metastases at the time of presentation.[29,30] If bone me-
tastases are suspected, further imaging is required. Currently, it 
is unclear which diagnostic modality is ideal for this, with the 
EAU suggesting an MRI, the AUA suggesting a bone scan, and 
the NCCN suggesting multiple modalities, including an MRI, 
a bone scan, or 18F-fluorodeoxyglucose positron emission to-
mography (PET)/CT.[29,31-33] Guidelines are less specific when 
it comes to brain metastases, but the NCCN recommends MRI 
with or without contrast in symptomatic or selected “high-risk” 
patients (e.g., small cell histology) or CT with contrast, if MRI 
is contraindicated.[30,34]
The role of routine PET imaging is currently undefined in the 
staging of bladder cancer, although some studies have demon-
strated increased sensitivity in detecting pelvic lymphadenopa-
thy nodes in advanced disease.[35] The current consensus by all 
4 guidelines is to avoid routine PET scanning during the ini-
tial staging evaluation, but to consider it; further evaluation is 
required in patients with abnormal findings or in whom lymph 
node biopsy is not feasible.[36]
Transurethral Resection of Bladder Tumor
All 4 major guidelines agree that TURBT is the most accurate 
and reliable technique to acquire a histopathological diagnosis 
and staging, if performed correctly.[1-4] All visible lesions should 
be resected piecemeal to ensure that a sample of the detrusor 
muscle is included in all the resections for appropriate staging. 
Each piece should ideally be labeled and packed in separate con-
tainers for analysis. The NICE further advises that random biop-
sies should not be taken from normal looking urothelium during 
TURBT, unless a specific clinical indication exists. In addition, 
both the NICE and the NCCN recommend a single dose of intra-
vesical chemotherapy (gemcitabine or mitomycin C) during the 
TURBT (or within the next 24 hours).[2,4] The EAU recommends 
that prostatic urethral biopsies should also be taken in cases 
of bladder neck tumors, presence or suspicion of CIS, visible 
prostatic urethral abnormalities, or where a positive cytology is 
noted in the absence of evidence of bladder tumor. If a urethral 
tumor is present, urethrectomy would be required, which would 
be a contraindication to neobladder formation.
Guideline Recommendations: Treatment
Once the bladder tumor has been appropriately staged, a multi-
disciplinary approach involving the patient is encouraged to for-
mulate an appropriate management plan. Treatment options are 
dependent on performance status and comorbidity and include 
partial or radical cystectomy, neoadjuvant or adjuvant therapy, 
bladder-preserving approaches, systemic therapy, and, in some 
selected cases, TURBT only.[37] A common comorbidity index 
used in bladder cancer is the age-adjusted Charlson comorbidity 
index, which has also been found to be an independent prog-
nostic factor for perioperative and overall mortality and cancer-
specific mortality.[38]
Turk J Urol
DOI: 10.5152/tud.2020.20337
Table 1. TNM classification of bladder cancer[17]
T - Primary Tumor
Non–muscle- 
invasive disease Tx Tumor cannot be assessed
 T0 No evidence of tumor
 Ta Noninvasive papillary carcinoma
 Tis Carcinoma in-situ: “flat tumor”
 T1 Subepithelial connective tissue invasion
Muscle-invasive  
disease T2 Muscularis propria muscle invasion
  pT2a Invasion of superficial  
   muscularis propria muscle  
   (inner half)
  pT2b Invasion of deep muscularis  
   propria muscle (outer half)
 T3 Perivesical tissue invasion 
  T3a Microscopic invasion
  T3b Macroscopic invasion  
   (extravesical mass)
 T4 Invasion of any of the following  
  structures: prostate stroma, seminal  
  vesicles, uterus, vagina, pelvic or  
  abdominal wall
  pT4a Prostate stroma, seminal  
   vesicles, uterus or vagina  
   involvement
  pT4b Pelvic or abdominal wall  
   involvement 
N: Regional lymph nodes
 Nx Regional lymph nodes cannot be  
  assessed
 N0 No regional lymph node metastasis
 N1 Metastasis in a single lymph node in the  
  true pelvis (hypogastric, obturator,  
  external iliac, or presacral)
 N2 Metastasis in multiple regional lymph  
  nodes in the true pelvis (hypogastric,  
  obturator, external iliac, or presacral)
 N3 Metastasis in a common iliac lymph 
  node(s)
M: Distant metastasis
 M0 No distant metastasis
  M1a Nonregional lymph nodes
  M1b Other distant metastasis
TNM: tumor, node, metastasis
Neoadjuvant therapies
The standard curative approach for MIBC (T2–4a, cN0M0) is 
radical cystectomy; however, this confers a 5-year survival of 
only 50%. As such, since the 1980s, cisplatin-based neoadjuvant 
chemotherapy has been routinely used to improve outcomes (ad-
ditional 8% at 5 years), unless contraindicated.[39]
Evidence on the use of neoadjuvant and/or adjuvant radiothera-
py is more limited, with no clear evidence of improved survival, 
or that it can be used with a curative intent. There are signs, 
however, that use of chemoradiotherapy (radiotherapy com-
bined with a radiosensitizer) can result in down-staging; there-
fore, the AUA, NICE, and NCCN recommend it in patients who 
are unable to undergo cystectomy.[1,2,4]
Immunotherapy is a future alternative to chemoradiotherapy, 
and currently, there are ongoing clinical trials assessing its ef-
fectiveness, the results of which are promising. As such, this 
treatment can only be offered to patients within a trial setting 
at this point.
Radical cystectomy
This is the standard of treatment for localized MIBC (T2–T4a, 
cN0M0) in most of the developed countries and should be 
performed within 3 months of initial resection.[40] The proce-
dure should ideally happen in high-volume centers because 
this is likely to improve the quality of care and reduce the 
perioperative morbidity and mortality. The procedure in-
volves a cystoprostatectomy in men and a cystectomy (with 
or without a hysterectomy) in women after the formation of 
a urinary diversion (i.e., a urinary stoma or continent urinary 
diversion) depending on contraindications. If a biopsy of the 
prostatic urethra has not been taken by this time, the EAU 
advises that a frozen section should be obtained at this point. 
Bilateral regional pelvic lymph node dissection should also 
be performed, but there remains a lack of evidence whether a 
limited or extended approach should be followed.[4] Laparo-
scopic and robotic-assisted laparoscopic cystectomy are alter-
natives to the open approach, but currently, they are still under 
investigation. Therefore, current best practice is open radical 
cystectomy.
Where possible, sexual function preserving procedures should 
be discussed with patients who are motivated to avoid sexual 
dysfunction and meet the requirements of an organ-confined 
disease lacking any bladder neck, urethra, or prostate involve-
ment.[1] In men, options include prostate, capsule, seminal, and 
nerve-sparing techniques; however, none have been shown 
to be superior so far. In women, there are less data regarding 
pelvic organ preservation. However, EAU guidelines suggest 
that it should be considered if sexual function preservation is 
desired. 
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Table 2. Summary of the surveillance plans recommended 
by the AUA, EAU, and NICE[1-3]
 Modality Interval
AUA Chest imaging+CT/MRI of  6–12 monthly for 2 to 3 
 abdomen and pelvis years and then annually 
 (Expert opinion) 
 Laboratory assessment 3–6 monthly for 2 to 3 years 
 (Expert opinion) and then annually 
 Monitor for disease recurrence  Unclear regarding 
 in the urethral remnant (if any)  frequency or method of 
 (Expert opinion) investigation (urethral wash  
  cytology versus physical  
  examination)
EAU CT scan of bladder+upper  6-monthly for 3 years and 
 urinary tract (if multifocal  then annually (stopped after 
 disease, NMIBC with CIS,  5 years) 
 trimodal treatment, or positive  
 ureteral margins) 
 Cystoscopy and/or cytology  Unclear 
 in selected patients, e.g.  
 multifocal tumor, CIS and  
 tumor in prostatic urethra
 If trimodal treatment used,  3–4 monthly follow-up for 
 regular follow-up is required  3 years and then 6-monthly 
 to avoid relapse  
 Cystoscopy 6-monthly
 CT of thorax and abdomen 3–4 monthly follow-up for  
  3 years and then 6-monthly  
  (stopped after 5 years)
 pH measurement (+sodium  Unclear 
 bicarbonate substitution)
 Vitamin B12 levels (if bowel  Annual 
 diversion used)
NICE CT thorax, abdomen, and  At 6, 12, and 24 months 
 pelvis after radical cystectomy or  
  radical radiotherapy
 Routine bloods: At least annually 
 Renal function  
 pH level 
 Vitamin B12 
 Folate
 If defunctioned urethra in Annually for 5 years 
 men: 
 Urethral washings for cytology  
 and/or urethroscopy 
 If radical radiotherapy,  Rigid cystoscopy 3 months 
 routine cystoscopy follow-up  after radiotherapy is 
 is required completed  
  Then rigid or flexible  
  cystoscopy: 
  3-monthly for 2 years 
  6-monthly for a further  
  2 years 
  Yearly thereafter (dependent 
  on clinical judgment and  
  patient preference)
 If radical radiotherapy,  Yearly for 5 years 
 regular upper tract imaging  
 is required
AUA: American Urological Association; EAU: European Association of Urology; 
NICE: National Institute for Health and Clinical Excellence; CT: computed 
tomography; MRI: magnetic resonance imaging; NMIBC: non–muscle-invasive 
bladder cancer; CIS: carcinoma in-situ.
Adjuvant therapies
In patients with MIBC who have not received neoadjuvant therapy, 
adjuvant cisplatin-based chemotherapy, chemoradiotherapy, or radio-
therapy can be considered depending on which guideline is followed. 
Unresectable tumor management
There is a consensus among the 4 major guidelines that in cases 
of locally advanced disease (T4b), no curative approach exists. In-
stead, patients should receive palliative treatments that are aimed 
at symptom relief. Options considered are palliative radiotherapy, 
chemotherapy, chemoradiotherapy, or, as a last resort, palliative 
cystectomy. However, the latter confers the greatest morbidity. 
Surveillance
The surveillance plans suggested by the 4 major guidelines are 
summarized in Tables 2 and 3, with the NCCN guideline being 
the most comprehensive.
Conclusion
The majority of the recommendations show significant consen-
sus among the guidelines because all of them are based on high-
quality evidence and expert opinions. In areas of discrepancies, 
the clinicians should follow a holistic approach catering to the 
individual patient characteristics to adopt the most appropriate 
management strategy on a case-by-case basis.
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